A randomized trial investigating the pharmacokinetics, pharmacodynamics, and safety of subcutaneous semaglutide once-weekly in healthy male Japanese and Caucasian subjects
Advances in Therapy Mar 21, 2018
Ikushima I, et al. - A comparative scrutiny was performed of the pharmacokinetics, pharmacodynamics, and safety of semaglutide in Japanese and Caucasian individuals for the treatment of type 2 diabetes. Findings revealed similar pharmacokinetic, pharmacodynamic, and safety profiles of semaglutide among Japanese and Caucasian subjects. Yielded data indicated that no dose adjustment was needed for the clinical use of semaglutide in Japanese subjects.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
